ROCHESTER, Minn. — Mayo Clinic researchers have uncovered new insights into lung adenocarcinoma, the most common type of lung cancer, in a study published in Cell Reports.

They say they discovered unknown genetic and cellular processes that could help improve immunotherapy responses. The research highlights the role of immune checkpoint inhibitors, drugs that enhance the body's ability to fight tumors. However, these drugs are not universally effective.

Alan P. Fields, Ph.D., a cancer biologist at Mayo Clinic, explained, "Our study describes the events that occur when a patient's tumor harbors only one copy of a cancer-causing gene, which occurs in 20% of cases."

The study found that the absence of the PRKCI gene results in less aggressive tumors and a stronger immune response, aide

See Full Page